35. An isolated compound having the structure:



wherein each X^1 and X^2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group at physiological pH;

wherein at least 96% of the bonds between the C and the B are in an L-configuration;

wherein A′ comprises an amino acid; and

wherein the compound inhibits DPIV activity.

36. The compound of claim 35, wherein X^1 and X^2 are hydroxyl groups.

37. The compound of claim 35, wherein at least 97% of the bonds between the C and the B are in an L-configuration.

38. The compound of claim 35, wherein at least 98% of the bonds between the C and the B are in an L-configuration.

39. The compound of claim 35, wherein 99% of the bonds between the C and the B are in an L-configuration.

40. The compound of claim 35, wherein A′ is valine.

42. An isolated compound having the structure:



wherein each X^1 and X^2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group at physiological pH:

wherein at least 96 % of the bonds between the C and the B are in an L-configuration;

wherein X comprises an amino acid or a peptide; and

wherein the compound inhibits DPIV activity.

43. The compound of claim 42, wherein X^1 and X^2 are hydroxyl groups.

44. The compound of claim 42, wherein at least 97% of the bonds between the C and the B are in an L-configuration.

45. The compound of claim 42, wherein at least 98% of the bonds between the C and the B are in an L-configuration.

46. The compound of claim 42, wherein 99% of the bonds between the C and the B are in an L-configuration.

47. The compound of claim 42, wherein X is an L-amino acid.

48. The compound of claim 43, wherein X is a peptide having the structure



wherein m is an integer between 0 and 10, inclusive; and

wherein A and A′ are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue.

49. The compound of claim 48, wherein A and A′ are independently proline or alanine residues.

50. The compound of claim 48, wherein m is an integer between 1 and 10.

51. The compound of claim 48, wherein m is 1.

In the Abstracts

Please delete the originally filed Abstract appearing on pages 30-33 of the application as filed and insert the following paragraph therefor:

--

Abstract

Peptide inhibitors of DP-IV are provided. The peptide inhibitors have an isomeric purity of about 96-99 percent. The peptide inhibitors include one or more amino acids covalently